These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 15867098

  • 1. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
    Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B.
    Endocr Rev; 2005 May; 26(3):361-79. PubMed ID: 15867098
    [Abstract] [Full Text] [Related]

  • 2. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F.
    Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
    [Abstract] [Full Text] [Related]

  • 3. GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer.
    Labrie F.
    Endocr Relat Cancer; 2014 Aug; 21(4):R301-17. PubMed ID: 24825748
    [Abstract] [Full Text] [Related]

  • 4. Hormonal therapy of prostate cancer.
    Labrie F.
    Prog Brain Res; 2010 Aug; 182():321-41. PubMed ID: 20541672
    [Abstract] [Full Text] [Related]

  • 5. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 6. Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.
    Labrie F, Cusan L, Gomez J, Luu-The V, Candas B, Bélanger A, Labrie C.
    J Steroid Biochem Mol Biol; 2004 Dec; 92(5):327-44. PubMed ID: 15698538
    [Abstract] [Full Text] [Related]

  • 7. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983 Dec; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 8. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
    Labrie F, Candas B, Gomez JL, Cusan L.
    Urology; 2002 Jul; 60(1):115-9. PubMed ID: 12100935
    [Abstract] [Full Text] [Related]

  • 9. Treatment of prostate cancer with gonadotropin-releasing hormone agonists.
    Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J, Monfette G.
    Endocr Rev; 1986 Feb; 7(1):67-74. PubMed ID: 3514203
    [Abstract] [Full Text] [Related]

  • 10. Endocrine therapy: where do we stand and where are we going?
    Schröder FH.
    Cancer Surv; 1991 Feb; 11():177-94. PubMed ID: 1841751
    [Abstract] [Full Text] [Related]

  • 11. Is dehydroepiandrosterone a hormone?
    Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G, Labrie C.
    J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766
    [Abstract] [Full Text] [Related]

  • 12. Endocrine therapy for prostate cancer.
    Damber JE.
    Acta Oncol; 2005 Nov; 44(6):605-9. PubMed ID: 16165920
    [Abstract] [Full Text] [Related]

  • 13. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S, Akaza H.
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [Abstract] [Full Text] [Related]

  • 14. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS, Fitzpatrick JM, Clarke N.
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [Abstract] [Full Text] [Related]

  • 15. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [Abstract] [Full Text] [Related]

  • 16. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [Abstract] [Full Text] [Related]

  • 17. Endocrine prevention and treatment of prostate cancer.
    Tammela TL.
    Mol Cell Endocrinol; 2012 Sep 05; 360(1-2):59-67. PubMed ID: 22465099
    [Abstract] [Full Text] [Related]

  • 18. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 05; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 19. Endocrine therapy for prostate cancer.
    Labrie F.
    Endocrinol Metab Clin North Am; 1991 Dec 05; 20(4):845-72. PubMed ID: 1778180
    [Abstract] [Full Text] [Related]

  • 20. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS, Blank J, Graff JN.
    Oncology (Williston Park); 2018 Dec 17; 32(12):599-602, 604-6. PubMed ID: 30632129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.